文献速递肝病消化道肿瘤与早癌

抑制细胞周期蛋白依赖性激酶5:改善肝细胞癌索拉非尼治疗反应的策略

Inhibition of Cyclin-Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy.
PubMed 文献 · Hepatology · 2018-12-22

晚期肝细胞癌治疗选择有限,索拉非尼反应率低且副作用严重。本研究通过基因敲低或药物抑制细胞周期蛋白依赖性激酶5(Cdk5),在体外和体内与索拉非尼联用协同抑制肿瘤进展,机制涉及干扰细胞内运输从而全面削弱生长因子受体信号。作者认为Cdk5抑制是改善索拉非尼反应的有效策略,并建议临床评估索拉非尼与Dinaciclib联用。

要点

  • 索拉非尼与Cdk5抑制(基因敲低或药物抑制)联用在体外和体内协同损害肝细胞癌进展。
  • Cdk5抑制通过干扰细胞内运输、导致囊泡及货物在核周区域积聚,削弱生长因子受体信号。
  • Cdk5是肝细胞癌中常过表达的可用靶点,临床已测试的Cdk5抑制剂Dinaciclib可用于联合评估。

核心结论

  • Cdk5抑制是改善索拉非尼反应并预防索拉非尼治疗逃逸的有效方法。
  • 作者认为本研究为临床评估索拉非尼与Dinaciclib联用以改善晚期肝细胞癌治疗状况提供了证据。

研究设计与样本

  • 研究采用体外和体内实验,通过基因敲低(短发夹RNA或CRISPR/Cas9)和药物抑制Cdk5,并与索拉非尼联用。
  • 采用基于液相色谱-串联质谱的蛋白质组学方法探讨Cdk5抑制的机制。

主要发现

  • 索拉非尼与Cdk5抑制联用在体外和体内协同损害肝细胞癌进展,抑制肿瘤细胞增殖和迁移。
  • Cdk5抑制干扰细胞内运输,导致增大的囊泡及相关货物在核周区域积聚,显著损害生长因子受体信号的程度和质量。
  • Cdk5抑制提供了一种全面干扰生长因子受体信号的方法,优于对单个生长因子受体的特异性抑制。

临床怎么用

  • 作者认为Cdk5抑制是改善索拉非尼反应和预防索拉非尼治疗逃逸的有效方法。
  • 作者建议临床评估索拉非尼与Dinaciclib联用以改善晚期肝细胞癌患者的治疗状况。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Therapeutic options for patients with advanced-stage hepatocellular carcinoma (HCC) are very limited. The only approved first-line treatment is the multi-tyrosine kinase inhibitor sorafenib, which shows low response rates and severe side effects. In particular, the compensatory activation of growth factor receptors leads to chemoresistance and limits the clinical impact of sorafenib. However, combination approaches to improve sorafenib have failed. Here we investigate the inhibition of cyclin-dependent kinase 5 (Cdk5) as a promising combination strategy to improve sorafenib response in HCC. Combination of sorafenib with Cdk5 inhibition (genetic knockdown by short hairpin RNA or CRISPR/Cas9 and pharmacologic inhibition) synergistically impaired HCC progression in vitro and in vivo by inhibiting both tumor cell proliferation and migration. Importantly, these effects were mediated by a mechanism for Cdk5: A liquid chromatography-tandem mass spectrometry-based proteomic approach revealed that Cdk5 inhibition interferes with intracellular trafficking, a process crucial for cellular homeostasis and growth factor receptor signaling. Cdk5 inhibition resulted in an accumulation of enlarged vesicles and respective cargos in the perinuclear region, considerably impairing the extent and quality of growth factor receptor signaling. Thereby, Cdk5 inhibition offers a comprehensive approach to globally disturb growth factor receptor signaling that is superior to specific inhibition of individual growth factor receptors. Conclusion: Cdk5 inhibition represents an effective approach to improve sorafenib response and to prevent sorafenib treatment escape in HCC. Notably, Cdk5 is an addressable target frequently overexpressed in HCC, and with Dinaciclib, a clinically tested Cdk5 inhibitor is readily available. Thus, our study provides evidence for clinically evaluating the combination of sorafenib and Dinaciclib to improve the therapeutic situation for patients with advanced-stage HCC.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Ardelt MA, Fröhlich T, Martini E, et al. Inhibition of Cyclin-Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy. Hepatology. 2018. PMID: 30033593. doi:10.1002/hep.30190

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。